Optimized Urine Liquid Biopsy Workflow: From Sample Collection To cfDNA Stabilization And Purification, Ready For Digital PCR Analysis

Cell-free DNA (cfDNA) found in urine is emerging as a promising avenue for liquid biopsy research. Unlike traditional methods that rely on blood samples, urine offers a truly non-invasive and easily accessible alternative for biomarker discovery. This makes it particularly attractive for routine monitoring and early detection applications. Notably, urine cfDNA is not limited to reflecting the status of the genitourinary tract; it also contains DNA fragments originating from non-urological tissues. This broadens its potential utility across various fields, including oncology and transplant medicine.

In addition to serving as a standalone source of diagnostic information, urine cfDNA has been shown to complement blood-derived cfDNA, which provides a more comprehensive molecular snapshot of a patient’s condition. Advances in analytical technologies, such as digital PCR (dPCR), have further enhanced the utility of urine cfDNA. Systems like the QIAcuity Digital PCR platform enable highly sensitive and precise quantification of DNA. This workflow also supports mutation detection, such as the PIK3CA H1047R variant, even after urine sample storage. Explore the end-to-end process from collection and stabilization to automated or manual cfDNA purification.

Gain insight into how these capabilities make urine cfDNA a valuable tool in cutting-edge biomedical research and clinical diagnostics.